198 related articles for article (PubMed ID: 12854132)
21. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression.
Kase H; Aoki Y; Tanaka K
Gynecol Oncol; 2003 Jul; 90(1):70-4. PubMed ID: 12821344
[TBL] [Abstract][Full Text] [Related]
22. Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.
Li M; Liu X; Zhou S; Li P; Li G
BMC Cancer; 2005 Aug; 5():96. PubMed ID: 16080799
[TBL] [Abstract][Full Text] [Related]
23. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
24. Relationship between expression of gastrin, somatostatin, Fas/FasL and caspases in large intestinal carcinoma.
Mao JD; Wu P; Yang YL; Wu J; Huang H
World J Gastroenterol; 2008 May; 14(18):2802-9. PubMed ID: 18473402
[TBL] [Abstract][Full Text] [Related]
25. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
26. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H
Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
[TBL] [Abstract][Full Text] [Related]
27. Expression of maspin and kai1 and their clinicopathological significance in carcinogenesis and progression of gastric cancer.
Zheng HC; Wang MC; Li JY; Yang XF; Sun JM; Xin Y
Chin Med Sci J; 2004 Sep; 19(3):193-8. PubMed ID: 15506646
[TBL] [Abstract][Full Text] [Related]
28. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
29. Epithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams VM; Straszewski SL; Kamsteeg M; Hanczaruk B; Schwartz PE; Rutherford TJ; Mor G
Cancer Res; 2003 Sep; 63(17):5573-81. PubMed ID: 14500397
[TBL] [Abstract][Full Text] [Related]
30. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
[TBL] [Abstract][Full Text] [Related]
31. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
[TBL] [Abstract][Full Text] [Related]
32. Expression of PTEN and Caspase-3 and their clinicopathological significance in primary gastric malignant lymphoma.
Sun H; Zheng H; Yang X; Wu D; Zhang S; Kuang L; Xin Y
Chin Med Sci J; 2004 Mar; 19(1):19-24. PubMed ID: 15104220
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes.
Meng Y; Graves L; Do TV; So J; Fishman DA
Gynecol Oncol; 2004 Dec; 95(3):488-95. PubMed ID: 15581951
[TBL] [Abstract][Full Text] [Related]
34. Anti-gastric cancer active immunity induced by FasL/B7-1 gene-modified tumor cells.
Zheng SY; Li DC; Zhang ZD; Zhao J; Ge JF
World J Gastroenterol; 2005 Jun; 11(21):3204-11. PubMed ID: 15929168
[TBL] [Abstract][Full Text] [Related]
35. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
36. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis.
Martin JH; Potthoff A; Ledig S; Cornberg M; Jandl O; Manns MP; Kubicka S; Flemming P; Athmann C; Beil W; Wagner S
Helicobacter; 2004 Oct; 9(5):371-86. PubMed ID: 15361075
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical analysis of apoptosis-related factors (Fas, Fas ligand, caspase-3 and single-stranded DNA) in ameloblastomas.
Kumamoto H; Kimi K; Ooya K
J Oral Pathol Med; 2001 Nov; 30(10):596-602. PubMed ID: 11722709
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.
Li Q; Peng J; Li XH; Liu T; Liang QC; Zhang GY
World J Gastroenterol; 2010 Mar; 16(10):1274-8. PubMed ID: 20222173
[TBL] [Abstract][Full Text] [Related]
39. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen.
Mor G; Kohen F; Garcia-Velasco J; Nilsen J; Brown W; Song J; Naftolin F
J Steroid Biochem Mol Biol; 2000; 73(5):185-94. PubMed ID: 11070347
[TBL] [Abstract][Full Text] [Related]
40. Fas ligand expression is correlated with metastasis in colorectal carcinoma.
Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
Oncology; 2003; 65(1):83-8. PubMed ID: 12837986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
